In addition, recent preclinical studies showed that TNFR2 blockade was enough to reduce the progression of breast cancer cell lines treated with TNFα (111) and that it promoted TNFα-associated lung cancer cell death (187). The gene discussed is TNFRSF1B; the disease is breast cancer.